Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dexcom Inc (NQ: DXCM )

76.34 +3.51 (+4.82%)
Streaming Delayed Price Updated: 11:02 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dexcom Inc

< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Here's How Much $100 Invested In DexCom 5 Years Ago Would Be Worth Today
DexCom (NASDAQ:DXCM) has outperformed the market over the past 5 years by 32.15% on an annualized basis producing an average annual return of 45.92%. Currently, DexCom has a market capitalization of... 
Via Benzinga
3 Top S&P 500 Stock Market Gainers Today: Medicals Lead As This Sector Reverses Hard
Medical and gold stocks led the S&P 500. Transport stocks were big losers. 
Via Investor's Business Daily
Dexcom Schedules First Quarter 2022 Earnings Release and Conference Call for April 28, 2022 at 4:30 p.m. Eastern Time
From DexCom, Inc.
Via Business Wire
Dexcom Stock Shows Market Leadership With Jump To 86 RS Rating
Dexcom shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 86. 
Via Investor's Business Daily
DexCom Stock Falls As Q4 Profit, FY22 Sales Outlook Trail Wall Street Estimates
DexCom Inc's (NASDAQ: DXCM)  
Via Benzinga
Earnings Scheduled For February 10, 2022
Companies Reporting Before The Bell • Canada Goose Hldgs (NYSE:GOOS) is projected to report quarterly earnings at $1.46 per share on revenue of $584.49 million. 
Via Benzinga
What 5 Analyst Ratings Have To Say About DexCom
Analysts have provided the following ratings for DexCom (NASDAQ:DXCM) within the last quarter: 
Via Benzinga
Markets Have Another Strong Week As S&P 500 Erases Initial Losses From Russia-Ukraine War
U.S. indices finished mixed Friday to conclude the trading week. Oil prices gained during Friday's session, which has continued to pressure economic sentiment. The S... 
Via Benzinga
Dexcom Announces Four-for-One Forward Stock Split
From DexCom, Inc.
Via Business Wire
Markets Fall In Anticipation Of This Week's Fed Decision
U.S. indices finished lower Monday amid continued Russia-Ukraine uncertainty, as well as in anticipation of this week’s Fed decision. The Nasdaq composite finished lower by... 
Via Benzinga
Dexcom G7 Receives CE Mark – Next-Generation Continuous Glucose Monitoring System to Revolutionize Diabetes Management
From DexCom, Inc.
Via Business Wire
Dexcom Snags A New Diabetes Device Win After Covid-Related Delay
Dexcom won out in Europe after the pandemic slowed its G7 CGM. 
Via Investor's Business Daily
Dexcom G7 Continuous Glucose Monitoring System Receives European CE Mark
DexCom Inc's (NASDAQ: DXCM) Dexcom G7 Continuous Glucose Monitoring (CGM) System has secured European CE Mark for people with diabetes aged two years and older... 
Via Benzinga
Could A Simple Device Help Revolutionize Medical Diagnostics? This Company Thinks So
Image provided by Know Labs This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Know... 
Via Benzinga
DexCom's Glucose Monitoring System Snags Breakthrough Device Tag For Hospital Use
The FDA granted Breakthrough Device Designation for DexCom Inc (NASDAQ: DXCM) for continuous glucose monitoring (CGM) use in the hospital setting. Dexcom CGM... 
Via Benzinga
Dexcom Announces Upcoming Virtual Conference Presentations
From DexCom, Inc.
Via Business Wire
The Daily Biotech Pulse: Adcom Recommends Additional Trials For Lilly's Partnered Cancer Drug, Novavax Touts Pediatric Vaccine Data, TC Biopharm IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adcom Rules That Lilly May Have To Conduct Additional Studies For Co-... 
Via Benzinga
Recap: DexCom Q4 Earnings
DexCom (NASDAQ:DXCM) reported its Q4 earnings results on Thursday, February 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings DexCom missed estimated earnings by... 
Via Benzinga
Dexcom Reports Fourth Quarter and Fiscal Year 2021 Financial Results
From DexCom, Inc.
Via Business Wire
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big... 
Via Benzinga
Dexcom G6 Continuous Glucose Monitoring System Now Covered in Alberta for Children and Youth Living With Diabetes
From Dexcom, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2022
Upgrades BTIG upgraded the previous rating for Insulet Corp (NASDAQ:PODD) from Neutral to Buy. For the third quarter, Insulet had an EPS of $0.18, compared to year-ago... 
Via Benzinga
7 Best Mutual Funds to Buy for February
Mutual funds are generally considered less risky. Here are seven mutual funds tailored to different investment objectives and risk profiles. 
Via InvestorPlace
Dexcom Schedules Fourth Quarter and Full Year 2021 Earnings Release and Conference Call for February 10, 2022 at 4:30 p.m. Eastern Time.
From DexCom, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2022
Upgrades For Rocket Companies Inc (NYSE:RKT), JP Mo... 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Raymond James cut DexCom, Inc. (NASDAQ:DXCM) pri... 
Via Benzinga
IRTC Stock: 17 Things to Know About iRhythm as Shares Rocket Higher Today
Irhythm Technologies (IRTC) stock is rising higher Monday alongside heavy trading of the shares and we know what's behind that movement! 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Molecular Partners (NASDAQ:MOLN) shares rose 26.6% to $20.9 during Monday's pre-market session. The company's market cap stands at $674.6 million. Apria (... 
Via Benzinga
Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter 2021 and Summary Data from the Dexcom G7 U.S. Pivotal Trial
From DexCom, Inc.
Via Business Wire
< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.